Xeris Biopharma Holdings, Inc. filings document the company’s commercial biopharmaceutical operations, financial results and governance as a Nasdaq-listed issuer. Its Form 8-K reports furnish quarterly and annual operating results, business highlights, financial guidance and product-related updates for Recorlev®, Gvoke® and Keveyis®.
The filing record also includes disclosure of Recorlev patent litigation under the Hatch-Waxman Act, involving Orange Book-listed patents and ANDA-related challenges. Proxy materials cover board composition, executive compensation, equity awards, shareholder voting matters and governance practices, while current reports document board changes and compensatory arrangements.
Xeris Biopharma Holdings, Inc. (XERS) reported that Chief Financial Officer Steven Pieper sold 5,000 shares of common stock on September 1, 2026 at a price of $8.50 per share. After this transaction, he directly holds 1,356,053 shares of XERS common stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.
Xeris Biopharma Holdings, Inc. (XERS) reported that its Chief Executive Officer and Chairman, Shannon John Patrick Jr, had 36,645 shares of common stock withheld on August 1, 2026. The shares were withheld by the company to satisfy income tax and withholding obligations upon net settlement of vested restricted stock units, not as an open-market sale. After this tax-withholding transaction, Patrick Jr directly holds 2,898,933 shares of XERS common stock.
Xeris Biopharma Holdings, Inc. (XERS) reported an insider equity-tax event by President and Chief Operating Officer Kevin McCulloch. On August 1, 2026, 21,918 shares of common stock were withheld by the company at $8.08 per share to satisfy income tax and withholding obligations on vested restricted stock units. After this tax-withholding disposition, McCulloch directly held 1,654,208 shares of common stock. An additional 25,000 shares are reported as indirectly owned by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. reported that its Chief Financial Officer, Steven Pieper, sold 5,000 shares of common stock on August 12, 2026 at a price of $8.50 per share. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025. Following this sale, Pieper continues to hold 1,361,053 shares of Xeris Biopharma common stock directly.
Xeris Biopharma Holdings, Inc. insider Steven Pieper filed to sell common stock under Rule 144. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed to handle the planned sale of 20,000 common shares on NASDAQ with an aggregate market value of $167,800.00. The shares relate to Restricted Stock Units granted on 01/03/2025. During the prior three months, Pieper reported 10b5-1 plan sales of 27,600 shares for $235,276.20 on 07/07/2026 and 17,400 shares for $147,900.00 on 07/06/2026.
Xeris Biopharma reported strong top-line growth for the quarter ended June 30, 2026, with total revenue $92.1 million versus $71.5 million a year earlier, driven mainly by Recorlev, whose net product revenue rose to $56.8 million for the quarter and $106.5 million year‑to‑date.
Higher volumes and improved product mix lifted income from operations to $5.2 million for the quarter and $13.1 million year‑to‑date, while cost of goods sold fell to 13.3% of product revenue for the first half. A $30.8 million loss on extinguishment of 2028 Convertible Notes, however, led to a quarterly net loss of $31.1 million and a first‑half net loss of $28.9 million, with stock‑based compensation of $15.2 million in the first half.
Cash and cash equivalents were $121.7 million at June 30, 2026, against total debt of $252.6 million and a stockholders’ deficit of $9.7 million. Management expects existing cash and cash flows to fund operations for at least 12 months while advancing XP‑8121 and managing ongoing Hatch‑Waxman patent litigation over Recorlev.
Xeris Biopharma Holdings reported strong growth for the three and six months ended June 30, 2026. Second quarter total revenue was $92.1 million, up 29% from $71.5 million a year earlier, driven by net product revenue of $91.0 million, which grew 34%. Recorlev revenue rose 81% to $56.8 million, while Gvoke slipped 4% and Keveyis grew 2%. Gross margin improved to 86% from 82%.
For the first half of 2026, total revenue reached $175.2 million, up 33%, with net product revenue of $173.5 million, up 38%. Adjusted EBITDA, a non-GAAP measure, was $19.3 million in the quarter and $34.4 million year-to-date, both higher than 2025. GAAP net loss widened to $31.1 million in the quarter and $28.9 million year-to-date, largely due to a one-time, non-cash charge of about $31 million related to 2028 Convertible Notes exchange agreements. Cash and cash equivalents were $121.7 million at June 30, 2026, and total shares outstanding were 182.3 million at July 31, 2026.
Xeris eliminated all outstanding 8.00% Convertible Senior Notes due 2028 by exchanging approximately $23.0 million of notes for $23.0 million in cash and about 5.0 million shares, and through conversion of another $10.5 million into about 3.6 million shares. The company tightened its 2026 total revenue guidance to $385–$390 million. It also received a Notice of Allowance for a new Keveyis patent expected to extend protection through at least 2039 and secured a new U.S. patent for its XP-8121 hypothyroidism candidate.
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on August 3, 2026 at a weighted average price of about $8.016 per share under a Rule 10b5-1 trading plan adopted on September 4, 2025, and now reports 1,676,126 shares held directly plus 25,000 shares held indirectly through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. reported that Chief Legal Officer and Corporate Secretary Beth Hecht sold 16,666 shares of common stock on August 3, 2026, in a sale classified as an open-market or private transaction at a weighted average price of $8.0135 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on August 8, 2025. Following this sale, she directly owned 1,144,462 shares of common stock. The shares were sold in multiple trades at prices between $7.870 and $8.140 per share.
Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of 8,637,640 shares of Xeris Biopharma Holdings Inc common stock, representing 5% of the class. Vanguard has sole voting power over 1,297,411 shares and sole dispositive power over all 8,637,640 shares, with no shared voting or dispositive power.
The position reflects securities held by various Vanguard funds and other managed accounts over which Vanguard or its affiliates exercise voting and/or dispositive authority. Vanguard states that no other single person has an interest in more than 5% of the securities reported.